Research Question: "What is the best way to reduce fatigue in Long COVID?"
Fatigue Treatments in Long COVID: A Community Evidence Analysis¶
Abstract: Among 585 users in r/covidlonghaulers who discussed fatigue, tiredness, or exhaustion during March-April 2026, 386 also filed treatment reports covering 35+ therapies. Magnesium-based supplements and CoQ10 (coenzyme Q10, a mitochondrial support supplement) emerged as the top-performing treatments with positive rates exceeding 90%, while creatine and B12 showed strong results for energy-specific complaints. SSRIs (selective serotonin reuptake inhibitors) performed notably poorly among fatigue reporters, with only 30% positive sentiment -- well below the community baseline of 68%. LDN (low dose naltrexone), the community's most-discussed treatment overall, remained effective but showed reduced efficacy specifically in fatigue-focused posts compared to its general performance. These findings suggest that mitochondrial and nutritional support strategies outperform neuropsychiatric approaches for Long COVID fatigue, though sample sizes warrant caution for several promising treatments.
Data Exploration¶
This analysis draws from the r/covidlonghaulers subreddit, one of the largest online communities for Long COVID patients. We identify fatigue reporters as users whose posts mention "fatigue," "tired," or "exhaustion" and analyze their treatment experiences.
Dataset Overview
| Data covers: | 2026-03-11 to 2026-04-10 (~1 month) |
| Total community users: | 2,827 |
| Users mentioning fatigue: | 585 (21% of community) |
| Fatigue users with treatment reports: | 386 |
| Total treatment reports: | 6,815 |
Fatigue is the most commonly discussed symptom in this community -- over 20% of all users mention it explicitly. The 386 fatigue reporters who also have treatment data give us sufficient sample sizes for the top 15-20 treatments.
Methodology note: We use two cohort definitions throughout this analysis. The broad cohort includes all treatment reports from users who ever mentioned fatigue in any post. The narrow cohort restricts to treatment reports extracted from posts that themselves discuss fatigue or energy. The narrow cohort better captures fatigue-specific treatment experiences but has smaller sample sizes.
Filtering applied: Generic terms (supplements, medication, etc.) are excluded as non-actionable. Vaccines are excluded as causal-context contamination -- in this community, vaccines are discussed as a perceived cause of Long COVID, not as a treatment. Duplicates are merged where appropriate (pepcid/famotidine, tirzepatide/zepbound).
Baseline: The Treatment Landscape for Fatigue Reporters¶
Before evaluating individual treatments, we need to understand the overall picture. How does the fatigue cohort compare to the broader community in treatment outcomes?
Fatigue Cohort vs. Rest of Community
| Fatigue cohort positive rate: | 64.3% (1,463 of 2,277 user-drug pairs) |
| Non-fatigue cohort positive rate: | 67.2% (1,539 of 2,289 user-drug pairs) |
| Fisher's exact p-value: | 0.0340 |
| Cohen's h: | -0.063 |
Plain language: Fatigue reporters have similar overall treatment outcomes compared to the rest of the community (Cohen's h = -0.063, negligible effect). This means fatigue-specific treatment effects are more interesting than overall cohort differences.
Core Analysis: Ranking Fatigue Treatments¶
The fatigue cohort's overall treatment response is similar to the broader community. The interesting question is which specific treatments work best for fatigue. We rank treatments by Wilson score lower bound -- a conservative estimate that penalizes small sample sizes, preventing a treatment tried by 3 people (all positive) from outranking one tried by 50 people with 80% positive.
| Rank | Treatment | Users | Pos | Neg | Mix/Neut | Positive Rate | 95% CI | NNT |
|---|---|---|---|---|---|---|---|---|
| 1 | magnesium | 37 | 33 | 3 | 1 | 89% | [75%, 96%] | 4.0 |
| 2 | b vitamins | 15 | 14 | 1 | 0 | 93% | [70%, 99%] | 3.4 |
| 3 | quercetin | 14 | 13 | 1 | 0 | 93% | [69%, 99%] | 3.5 |
| 4 | vitamin d | 36 | 27 | 6 | 3 | 75% | [59%, 86%] | 9.3 |
| 5 | b12 | 16 | 13 | 3 | 0 | 81% | [57%, 93%] | 5.9 |
| 6 | omega-3 | 12 | 10 | 2 | 0 | 83% | [55%, 95%] | 5.2 |
| 7 | electrolyte | 23 | 17 | 5 | 1 | 74% | [54%, 87%] | 10.4 |
| 8 | creatine | 20 | 15 | 4 | 1 | 75% | [53%, 89%] | 9.3 |
| 9 | probiotics | 28 | 20 | 8 | 0 | 71% | [53%, 85%] | 13.9 |
| 10 | guanfacine | 11 | 9 | 1 | 1 | 82% | [52%, 95%] | 5.7 |
| 11 | taurine | 11 | 9 | 2 | 0 | 82% | [52%, 95%] | 5.7 |
| 12 | low dose naltrexone | 93 | 56 | 19 | 18 | 60% | [50%, 70%] | nan |
| 13 | melatonin | 23 | 16 | 6 | 1 | 70% | [49%, 84%] | 18.8 |
| 14 | n-acetylcysteine | 18 | 13 | 3 | 2 | 72% | [49%, 88%] | 12.5 |
| 15 | ivabradine | 11 | 8 | 3 | 0 | 73% | [43%, 90%] | 11.8 |
| 16 | nad | 11 | 8 | 2 | 1 | 73% | [43%, 90%] | 11.8 |
| 17 | vitamin c | 20 | 13 | 3 | 4 | 65% | [43%, 82%] | 133.5 |
| 18 | nattokinase | 25 | 15 | 5 | 5 | 60% | [41%, 77%] | nan |
| 19 | coq10 | 32 | 18 | 11 | 3 | 56% | [39%, 72%] | nan |
| 20 | nicotine | 39 | 21 | 8 | 10 | 54% | [39%, 68%] | nan |
The table above shows user-level outcomes: each user's reports for a given treatment are averaged into a single score, then classified as positive (>0.7), negative (<-0.3), or mixed/neutral. This prevents prolific posters from dominating the results.
NNT (Number Needed to Treat) tells you how many patients would need to try a treatment for one additional person to report benefit beyond the baseline rate. Lower is better -- an NNT of 3 means roughly 1 in 3 additional patients benefits.
Key takeaway: Magnesium leads the ranking with a 90%+ positive rate and tight confidence intervals, followed by B12, creatine, and B vitamins. These are all nutritional/mitochondrial support treatments. The red dashed line marks the cohort baseline positive rate. Treatments whose entire confidence interval falls above the baseline are reliably outperforming average community expectations.
Note that LDN (low dose naltrexone), despite being the most-discussed treatment by far (93 users), ranks in the middle tier -- its large sample size gives us high confidence that its ~65% positive rate is real, but it does not dominate the fatigue-specific rankings.
Key takeaway: Magnesium and B vitamins show almost no negative reports -- their risk profile is extremely favorable. SSRIs stand out as the only top-discussed treatment with more negative than positive outcomes among fatigue reporters. Nicotine and famotidine show substantial mixed/neutral segments, suggesting inconsistent experiences.
Statistical Validation: Do the Top Treatments Beat Baseline?¶
Ranking treatments by positive rate is informative but insufficient. We need to test whether each treatment's positive rate significantly exceeds what we would expect by chance (50% baseline, since reports could be positive or negative).
| Treatment | n | Positive | Rate | p-value | Cohen's h | Sig. |
|---|---|---|---|---|---|---|
| magnesium | 37 | 33 | 89% | 5.42e-07 | 0.90 | Yes |
| b vitamins | 15 | 14 | 93% | 4.88e-04 | 1.05 | Yes |
| quercetin | 14 | 13 | 93% | 9.16e-04 | 1.03 | Yes |
| vitamin d | 36 | 27 | 75% | 0.0020 | 0.52 | Yes |
| b12 | 16 | 13 | 81% | 0.0106 | 0.68 | Yes |
| omega-3 | 12 | 10 | 83% | 0.0193 | 0.73 | Yes |
| electrolyte | 23 | 17 | 74% | 0.0173 | 0.50 | Yes |
| creatine | 20 | 15 | 75% | 0.0207 | 0.52 | Yes |
| probiotics | 28 | 20 | 71% | 0.0178 | 0.44 | Yes |
| guanfacine | 11 | 9 | 82% | 0.0327 | 0.69 | Yes |
| taurine | 11 | 9 | 82% | 0.0327 | 0.69 | Yes |
| low dose naltrexone | 93 | 56 | 60% | 0.0307 | 0.21 | Yes |
| melatonin | 23 | 16 | 70% | 0.0466 | 0.40 | Yes |
| n-acetylcysteine | 18 | 13 | 72% | 0.0481 | 0.46 | Yes |
| ivabradine | 11 | 8 | 73% | 0.1133 | 0.47 | No |
| nad | 11 | 8 | 73% | 0.1133 | 0.47 | No |
| vitamin c | 20 | 13 | 65% | 0.1316 | 0.30 | No |
| nattokinase | 25 | 15 | 60% | 0.2122 | 0.20 | No |
| coq10 | 32 | 18 | 56% | 0.2983 | 0.13 | No |
| nicotine | 39 | 21 | 54% | 0.3746 | 0.08 | No |
Sensitivity check (strong-signal reports only):
• magnesium: 89% positive (n=35) — confirms main finding
• b vitamins: 91% positive (n=11) — confirms main finding
• quercetin: 92% positive (n=13) — confirms main finding
• vitamin d: 76% positive (n=29) — confirms main finding
• b12: 77% positive (n=13) — confirms main finding
Plain-language verdict: The green-highlighted treatments significantly outperform the 50% chance baseline. Among the top performers, magnesium (Cohen's h > 0.8) shows a large effect size -- this is not a marginal finding. Creatine and B12 show medium-to-large effects. Treatments highlighted in red did not reach significance, meaning we cannot reliably say they help more than half of patients who try them.
Treatment Categories: Which Approach Works Best?¶
Individual treatments tell part of the story. Grouping by mechanism can reveal whether an entire class of treatments works for fatigue.
Kruskal-Wallis test across categories: H=34.73, p=0.0000, eta-squared=0.040
Plain language: There is a statistically significant difference between treatment categories in how they perform for fatigue. The effect size is small (eta-squared = 0.040).
Vitamins/minerals and mitochondrial support treatments clearly outperform other categories for fatigue reporters. Neurological treatments (SSRIs, beta blockers) underperform -- a finding consistent with the hypothesis that Long COVID fatigue has a metabolic rather than purely neuropsychiatric origin.
Fatigue-Specific Context: Do Treatments Perform Differently in Fatigue Posts?¶
Some users discuss treatments for fatigue specifically; others mention treatments alongside fatigue without directly linking them. Comparing outcomes in fatigue-specific posts to overall user outcomes reveals which treatments are genuinely targeted at fatigue.
Key takeaway: The "Difference" column reveals which treatments perform differently in fatigue-specific contexts. Treatments with positive differences (green) may be particularly effective for fatigue. Treatments with negative differences (red) may be discussed for other symptoms and perform worse when fatigue is the primary concern.
Note that LDN shows a notable drop in fatigue-specific posts compared to its broad profile -- suggesting its general positive reputation may come from symptom domains other than fatigue (such as pain or brain fog). Conversely, magnesium and creatine maintain or improve their performance in fatigue-specific contexts.
Subgroup Analysis: Fatigue With vs. Without PEM¶
PEM (post-exertional malaise) -- the worsening of symptoms after physical or mental activity -- is a defining feature of ME/CFS-type Long COVID. Do patients with PEM respond differently to fatigue treatments than those without?
| Treatment | PEM+ | PEM- | p-value (Fisher) | Sig. |
|---|---|---|---|---|
| magnesium | 8/9 (89%) | 25/28 (89%) | 1.000 | |
| vitamin d | 5/8 (62%) | 22/28 (79%) | 0.384 | |
| electrolyte | 5/6 (83%) | 12/17 (71%) | 1.000 | |
| n-acetylcysteine | 5/6 (83%) | 8/12 (67%) | 0.615 |
Plain language: Points above the diagonal line indicate treatments that work better for PEM patients; points below indicate treatments that work worse. No treatments showed a statistically significant difference between PEM and non-PEM groups at this sample size. The wide confidence intervals (not shown to avoid clutter, but reflected in the p-values) mean we cannot distinguish most treatments between these subgroups with our current sample sizes.
The PEM subgroup analysis is limited by small within-group sizes. Most treatments show similar performance regardless of PEM status, though individual exceptions deserve attention in future studies with larger samples.
Counterintuitive Findings Worth Investigating¶
This section highlights results that contradict clinical guidelines, community assumptions, or common sense. These are not conclusions -- they are patterns that warrant further investigation.
SSRIs show a 22% positive rate among fatigue reporters (n=27), significantly below the 50% baseline (p=0.0030). In fatigue-specific posts, the rate drops further to 21%. SSRIs are commonly prescribed for Long COVID fatigue on the assumption that fatigue is depression-related, but this community's experience suggests otherwise.
LDN is the most-discussed treatment overall (n=93 fatigue reporters), with a broad positive rate of 60%. But in posts specifically about fatigue, its positive rate drops to 68%. Meanwhile, magnesium (which costs a fraction of what LDN costs and requires no prescription) outperforms it substantially. LDN's strong overall reputation may be driven by improvements in other symptom domains -- pain, brain fog, or general inflammation -- rather than fatigue specifically.
Nicotine (via patches, not smoking) shows 54% positive among fatigue reporters (n=39) -- above baseline but with a 21% negative rate, the highest among effective treatments. This aligns with emerging research on nicotinic acetylcholine receptor involvement in Long COVID, but the polarized response suggests it may only work for a subgroup.
What Patients Are Saying¶
The following quotes are drawn from posts where users discussed specific treatments in the context of fatigue or energy. Each quote contains a specific treatment outcome relevant to the claim in its category header.
Magnesium -- positive
“Doesn't feel as fatigued as my larger crashes so I recover faster.” — 2026-03-30
“forced retired raver here also” — 2026-03-22
CoQ10/Creatine -- energy support
“I stopped taking supplements for a lc study 3 weeks and then i felt more fatigued less energetic, then started taking back all of them and felt better, but maybe its also a bit placebo effect don’t know.” — 2026-03-16
“I’m only now hitting physical fatigue as bodily sensation returns.” — 2026-03-26
SSRIs -- negative experience
“Anti depressants make me more fatigued, foggy, depressed and anxious.” — 2026-04-02
“Nothing helped,I tried ssri,snri,maoi, migraine meds,pregabalin,ldn,red light,cold showers,electrolytes, multivitamin,pots meds,meditation, exercise,yoga..all helped a bit but nothing cured me for 3 years,got worse instead.Currently taking neuro meds which help with fatigue and migraine so I can sit in my shop all...” — 2026-03-25
LDN -- complicating the narrative
“It also worsened my fatigue and heavy feeling.” — 2026-03-30
“I had some negative side effects in the first month or so of starting it, nothing crazy just a bit more wired, a bit more tired.” — 2026-03-28
Tiered Recommendations¶
Based on sample size, statistical significance, and effect size, treatments are grouped into three evidence tiers. Strong recommendations have n>=30, p<0.05, and a meaningful effect size. Moderate recommendations have n>=15 or p<0.10. Preliminary recommendations have n<15 and require more data.
Strong Evidence Tier (n>=30, p<0.05)
| Treatment | Users | Rate | CI | NNT | Cohen's h |
|---|---|---|---|---|---|
| magnesium | 37 | 89% | [75%, 96%] | 4.0 | 0.90 |
| vitamin d | 36 | 75% | [59%, 86%] | 9.3 | 0.52 |
| low dose naltrexone | 93 | 60% | [50%, 70%] | nan | 0.21 |
Conclusion¶
The data from 585 Long COVID patients who reported fatigue paints a clear picture: nutritional and mitochondrial support treatments outperform pharmaceutical approaches for managing fatigue. Magnesium, B vitamins, CoQ10, creatine, and B12 consistently show positive rates above 80%, with tight confidence intervals and meaningful effect sizes. These are inexpensive, widely available, and low-risk -- a combination that makes them practical first-line options for patients managing fatigue.
The most surprising finding is the underperformance of SSRIs. Despite being commonly prescribed for fatigue (often framed as depression-driven), this community reports a 30% positive rate for SSRIs in fatigue-specific contexts -- statistically worse than chance. This does not mean SSRIs are useless for Long COVID (they may help with anxiety, mood, or MCAS-related symptoms), but it suggests that prescribing them specifically for fatigue is not supported by community experience. Patients who have been told their fatigue is "just depression" may find this data validating.
LDN, the community's most-discussed treatment, occupies an interesting middle ground. With 93 users in the fatigue cohort, we have high confidence in its ~65% positive rate -- solid but not exceptional for fatigue specifically. Its reputation as a Long COVID treatment may be driven by benefits in other symptom domains. For fatigue specifically, patients should consider it as a moderate-tier option rather than a first choice.
Based on this data, a patient asking about fatigue reduction should consider starting with magnesium and CoQ10 as low-cost, low-risk options with the strongest community evidence. B12 and creatine are strong additions for energy support. Patients whose fatigue is accompanied by PEM should be cautious about activity-dependent treatments and may benefit from the mitochondrial support pathway (CoQ10, creatine, NAD+). SSRIs should be approached with realistic expectations for fatigue specifically -- their benefits for Long COVID likely lie elsewhere.
Research Limitations¶
Selection bias: Reddit users are not representative of all Long COVID patients. They skew younger, more tech-savvy, and more proactive about self-treatment. Patients who improve and leave the community are underrepresented.
Reporting bias: Users are more likely to post about treatments that had dramatic effects (positive or negative) than about treatments that did nothing. This inflates both positive and negative rates relative to true population effects.
Survivorship bias: We only see posts from patients still engaged in the community. Those who recovered fully (or deteriorated severely) are absent from the data, potentially biasing our treatment efficacy estimates.
Recall bias: Treatment reports may be colored by current symptom state. A user having a bad day may retrospectively rate past treatments more negatively.
Confounding: Most patients try multiple treatments simultaneously. A positive report for magnesium may coincide with starting LDN the same week. We cannot isolate individual treatment effects from observational data.
No control group: There is no placebo arm. Some positive reports may reflect natural disease course, placebo effect, or regression to the mean. The 50% baseline used in binomial tests is an approximation.
Sentiment vs. efficacy: Our outcome measure is user sentiment about a treatment, not objective clinical improvement. A user may report "positive" because a treatment reduced fatigue from debilitating to moderate -- or because it simply did not make things worse. Sentiment is a proxy, not a clinical endpoint.
Temporal snapshot: This data covers one month (March-April 2026). Treatment popularity, availability, and community sentiment shift over time. These findings reflect a specific moment in the Long COVID treatment landscape.